Immudex launches dCODE Dextramer® (RiO), a new reagent compatible with BD Rhapsody™ Single Cell Analysis systemFebruary 1, 2021
Immudex ApS has been collaborating with BD (Becton, Dickinson and Company) to create improved solutions for T-cell multi-omics research. The goal of this collaboration was to develop dCODE Dextramer® reagents compatible with the BD Rhapsody™ Single Cell Analysis system, a platform that analyzes the expression of hundreds of genes across tens of thousands of single cells in parallel.
Today, we are proud to announce the launch of dCODE Dextramer® (RiO) reagents. These DNA barcoded MHC Dextramer® reagents are designed to be compatible with the BD Rhapsody™ system to be used for multiplexing, allowing the identification of many different T-cell specificities in the same sample. Creating personalized dCODE Dextramer® libraries, is possible to profile T cells and get a new understanding of T-cell immunity.
“At Immudex, we are working with a clear goal in mind, helping researchers worldwide to get a better understanding of cellular immunity.” Says Liselotte Brix, CSO at Immudex. “The immune system is complex, and there is still a lot to be discovered. dCODE Dextramer® (RiO) technology combined with the BD Rhapsody™ single-cell multi-omic analysis provides a deeper understanding of T cell immunology in a user-friendly workflow by combining information on TCR recognition with gene and surface marker expression at the single-cell level. Such information helps unlock new insights into the immune response, accelerating basic research, immunotherapeutic development, and improving patient outcomes"
The dCODE Dextramer® technology is an extremely sensitive method to directly detect disease-specific T cells based on TCR recognition and DNA barcode labels. Combining dCODE® technology with BD’s multi-omics solutions for immunology, researchers can obtain a full immunological profiling in one workflow and get the most of their experiments.
dCODE Dextramer® (RiO) reagents are for research use only, not for use in diagnostic or therapeutic procedures, and have been manufactured by Immudex ApS.
Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex is the sole proprietor of DNA barcoded MHC multimer technology. The dCODE Dextramer® technology is an advanced development of Immudex proprietary MHC Dextramer® reagents, which are superior for the detection of antigen-specific T cells. The dCODE® technology enables massive multiplexing of disease-specific T-cell detection overcoming the limitations of earlier technologies. Find out more at www.immudex.com.
Omics & Genetics,